Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Masanori Onda"'
Autor:
Frieder Bauss, Martin Lechmann, Ben-Fillippo Krippendorff, Roland Staack, Frank Herting, Matthias Festag, Sabine Imhof-Jung, Friederike Hesse, Marc Pompiati, Gwendlyn Kollmorgen, Rita da Silva Mateus Seidl, Birgit Bossenmaier, Wilma Lau, Christian Schantz, Jan O. Stracke, Ulrich Brinkmann, Masanori Onda, Ira Pastan, Klaus Bosslet, Gerhard Niederfellner
Publikováno v:
Molecular Oncology, Vol 10, Iss 8, Pp 1317-1329 (2016)
Mesothelin overexpression in lung adenocarcinomas correlates with the presence of activating KRAS mutations and poor prognosis. Hence SS1P, a mesothelin‐targeted immunotoxin, could offer valuable treatment options for these patients, but its use in
Externí odkaz:
https://doaj.org/article/016854fb9481433287e7d8721af2694e
Autor:
Gilad Kaplan, Fred Lee, Masanori Onda, Emily Kolyvas, Gaurav Bhardwaj, David Baker, Ira Pastan
Publikováno v:
Toxins, Vol 8, Iss 8, p 217 (2016)
Recombinant immunotoxins (RITs) are fusions of an Fv-based targeting moiety and a toxin. Pseudomonas exotoxin A (PE) has been used to make several immunotoxins that have been evaluated in clinical trials. Immunogenicity of the bacterial toxin and off
Externí odkaz:
https://doaj.org/article/a5d0ac70bdad47c1a8a33c4c52f89d38
Autor:
Ira Pastan, Raffit Hassan, Masanori Onda, Dawn A. Walker, Richard Beers, Jingli Zhang, Laiman Xiang, John E. Weldon
PDF file - 71K, In vitro cytotoxicity summary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39da543360e8010bbca5b5006765636b
https://doi.org/10.1158/1535-7163.22499139.v1
https://doi.org/10.1158/1535-7163.22499139.v1
Autor:
Ira Pastan, Raffit Hassan, Masanori Onda, Dawn A. Walker, Richard Beers, Jingli Zhang, Laiman Xiang, John E. Weldon
SS1P is a recombinant immunotoxin (RIT) engineered for the targeted elimination of malignant cells that express the tumor-associated antigen mesothelin. It is composed of an antimesothelin antibody variable fragment (Fv) linked to a cytotoxic fragmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f93f028748e7f0bad1e0e2bb797b26f
https://doi.org/10.1158/1535-7163.c.6536079
https://doi.org/10.1158/1535-7163.c.6536079
Autor:
Ira Pastan, Raffit Hassan, Masanori Onda, Dawn A. Walker, Richard Beers, Jingli Zhang, Laiman Xiang, John E. Weldon
PDF file - 231K, Human antigenicity of SS1-LR/GGS/8M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d5ca07d5478f1efad098d479dfc1487
https://doi.org/10.1158/1535-7163.22499148
https://doi.org/10.1158/1535-7163.22499148
Autor:
Ira Pastan, Raffit Hassan, Masanori Onda, Dawn A. Walker, Richard Beers, Jingli Zhang, Laiman Xiang, John E. Weldon
PDF file - 204K, Pharmacokinetics of SS1-LR/GGS/8M in mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0110207e882196927516673dc08b7e2c
https://doi.org/10.1158/1535-7163.22499151.v1
https://doi.org/10.1158/1535-7163.22499151.v1
Autor:
Ira Pastan, Raffit Hassan, Masanori Onda, Dawn A. Walker, Richard Beers, Jingli Zhang, Laiman Xiang, John E. Weldon
PDF file - 605K, Relative cytotoxicity in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54e8656472f3b28f029f3a8a204c73de
https://doi.org/10.1158/1535-7163.22499154
https://doi.org/10.1158/1535-7163.22499154
Autor:
Ira Pastan, Raffit Hassan, Masanori Onda, Dawn A. Walker, Richard Beers, Jingli Zhang, Laiman Xiang, John E. Weldon
PDF file - 626K, Purified recombinant immunotoxins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00cffbd935ea0b7084758b2e86b1cd8f
https://doi.org/10.1158/1535-7163.22499157
https://doi.org/10.1158/1535-7163.22499157
Autor:
Vincent Chen, Shigeki Umemura, Yumin Han, Renuka Raman, Robin Tucker, Joeffrey Chahine, In-Kyu Kim, Christoph Schatz, Sabine Zitzmann-Kolbe, Anette Sommer, Masanori Onda, Trevor Lee, Yongfeng He, Giuseppe Giaccone
Publikováno v:
Br J Cancer
BACKGROUND: Thymic epithelial tumours (TETs) are rare tumours comprised of thymomas and thymic carcinoma. Novel therapies are needed, especially in thymic carcinoma where the 5-year survival rate hovers at 30%. Mesothelin (MSLN), a surface glycoprote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0370760f71a56fb2650cb94aa7be8ef9
https://doi.org/10.1038/s41416-021-01658-6
https://doi.org/10.1038/s41416-021-01658-6